TY - JOUR
T1 - Role of gastrointestinal endoscopy in the screening of digestive tract cancers in Europe
T2 - European Society of Gastrointestinal Endoscopy (ESGE) Position Statement
AU - Sǎftoiu, Adrian
AU - Hassan, Cesare
AU - Areia, Miguel
AU - Bhutani, Manoop S.
AU - Bisschops, Raf
AU - Bories, Erwan
AU - Cazacu, Irina M.
AU - Dekker, Evelien
AU - Deprez, Pierre H.
AU - Pereira, Stephen P.
AU - Senore, Carlo
AU - Capocaccia, Riccardo
AU - Antonelli, Giulio
AU - Van Hooft, Jeanin
AU - Messmann, Helmut
AU - Siersema, Peter D.
AU - Dinis-Ribeiro, Mario
AU - Ponchon, Thierry
N1 - Publisher Copyright:
© 2020 Georg Thieme Verlag. All rights reserved.
PY - 2020/4/1
Y1 - 2020/4/1
N2 - Summary of statements In Europe at present, but also in 2040, 1 in 3 cancer-related deaths are expected to be caused by digestive cancers. Endoscopic technologies enable diagnosis, with relatively low invasiveness, of precancerous conditions and early cancers, thereby improving patient survival. Overall, endoscopy capacity must be adjusted to facilitate both effective screening programs and rigorous control of the quality assurance and surveillance systems required. 1 For average-risk populations, ESGE recommends the implementation of organized population-based screening programs for colorectal cancer, based on fecal immunochemical testing (FIT), targeting individuals, irrespective of gender, aged between 50 and 75 years. Depending on local factors, namely the adherence of the target population and availability of endoscopy services, primary screening by colonoscopy or sigmoidoscopy may also be recommendable. 2 In high-risk populations, endoscopic screening for gastric cancer should be considered for individuals aged more than 40 years. Its use in countries/regions with intermediate risk may be considered on the basis of local settings and availability of endoscopic resources. 3 For esophageal and pancreatic cancer, endoscopic screening may be considered only in high-risk individuals: - For squamous cell carcinoma, in those with a personal history of head/neck cancer, achalasia, or previous caustic injury; - For Barrett's esophagus (BE)-associated adenocarcinoma, in those with long-standing gastroesophageal reflux disease symptoms (i.?e.,?>?5 years) and multiple risk factors (age?≥?50 years, white race, male sex, obesity, first-degree relative with BE or esophageal adenocarcinoma [EAC]). - For pancreatic cancer screening, endoscopic ultrasound may be used in selected high-risk patients such as those with a strong family history and/or genetic susceptibility.
AB - Summary of statements In Europe at present, but also in 2040, 1 in 3 cancer-related deaths are expected to be caused by digestive cancers. Endoscopic technologies enable diagnosis, with relatively low invasiveness, of precancerous conditions and early cancers, thereby improving patient survival. Overall, endoscopy capacity must be adjusted to facilitate both effective screening programs and rigorous control of the quality assurance and surveillance systems required. 1 For average-risk populations, ESGE recommends the implementation of organized population-based screening programs for colorectal cancer, based on fecal immunochemical testing (FIT), targeting individuals, irrespective of gender, aged between 50 and 75 years. Depending on local factors, namely the adherence of the target population and availability of endoscopy services, primary screening by colonoscopy or sigmoidoscopy may also be recommendable. 2 In high-risk populations, endoscopic screening for gastric cancer should be considered for individuals aged more than 40 years. Its use in countries/regions with intermediate risk may be considered on the basis of local settings and availability of endoscopic resources. 3 For esophageal and pancreatic cancer, endoscopic screening may be considered only in high-risk individuals: - For squamous cell carcinoma, in those with a personal history of head/neck cancer, achalasia, or previous caustic injury; - For Barrett's esophagus (BE)-associated adenocarcinoma, in those with long-standing gastroesophageal reflux disease symptoms (i.?e.,?>?5 years) and multiple risk factors (age?≥?50 years, white race, male sex, obesity, first-degree relative with BE or esophageal adenocarcinoma [EAC]). - For pancreatic cancer screening, endoscopic ultrasound may be used in selected high-risk patients such as those with a strong family history and/or genetic susceptibility.
UR - http://www.scopus.com/inward/record.url?scp=85082388335&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85082388335&partnerID=8YFLogxK
U2 - 10.1055/a-1104-5245
DO - 10.1055/a-1104-5245
M3 - Article
C2 - 32052404
AN - SCOPUS:85082388335
SN - 0013-726X
VL - 52
SP - 293
EP - 304
JO - Endoscopy
JF - Endoscopy
IS - 4
ER -